KRRO - NASDAQ

Korro Bio, Inc.

KRRO·NASDAQ

$11.08

+2.1%

HealthcareBiotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$110.28M

EPS-12.4800

P/E Ratio-0.89

Earnings Date08/11/2026

113.51M

Assets

-50%

3Y+54.0%

5Y-57.0%

10Y+474.0%

62.07M

Total Liabilities

-6%

3Y-64.0%

5Y-14.0%

10Y+26.0%

51.44M

Total Equity

-68%

3Y-152.0%

5Y-73.0%

10Y-274.0%

Korro Bio, Inc. Funding & Solvency Profile

KRRO · NASDAQ

Current Assets

Cash & Cash Equivalents21.82M

Net Receivables969.00K

Inventory0.00

Other Current Assets6.25M

Total Current Assets82 M

Non-Current Assets

Property, Plant & Equipment16.22M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets14.91M

Total Non-Current Assets31 M

Total Assets

113.51M

Financial Health Analysis

Current Ratio

6.90x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.21x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

70 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

73% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Korro Bio, Inc. Balance Sheet

KRRO • NASDAQ

Korro Bio, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	21.8M	55.6M	166.2M	36.9M	79.6M	220.3M	200.2M	42.2M	17.9M
Short-Term Investments	53.3M	70.5M	0.0	18.9M	51.1M	0.0	17.2M	0.0	0.0
Cash & Short-Term Investments	75.2M	126.1M	166.2M	55.9M	130.7M	220.3M	217.4M	42.2M	17.9M
Net Receivables	969K	1.7M	0.0	0.0	144K	340K	805K	161K	0.0
Accounts Receivables	969K	1.7M	0.0	449K	144K	340K	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	-449K	0.0	0.0	805K	161K	0.0
Prepaids	0.0	0.0	3M	1.6M	2.9M	2.6M	2.2M	0.0	3K
Other Current Assets	6.2M	3.7M	3.6M	-376K	1M	1.8M	1M	587K	15K
Total Current Assets	82.4M	131.5M	172.7M	57.1M	134.7M	225.1M	221.4M	42.9M	18M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	16.2M	51.5M	42.8M	11.9M	36.9M	37.8M	1.8M	1.5M	1.7M
Long-Term Investments	0.0	37M	0.0	4.5M	13.4M	1.8M	0.0	0.0	0.0
Other Non-Current Assets	14.9M	6.2M	6.1M	228K	320K	0.0	101K	100K	103K
Total Non-Current Assets	31.1M	94.7M	48.9M	16.7M	50.6M	39.7M	1.9M	1.6M	1.8M
Total Assets	113.5M	226.2M	221.7M	73.7M	185.4M	264.7M	223.2M	44.5M	19.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.7M	4M	7.3M	2.6M	2.7M	5.5M	1.2M	1.9M	994K
Accounts Payable	1.7M	4M	7.3M	2.6M	2.7M	5.5M	1.2M	1.9M	994K
Accrued Expenses	0.0	2.1M	9.8M	2.6M	4.4M	5.1M	0.0	1M	752K
Short Term Debt	2.7M	0.0	0.0	2.9M	2.6M	397K	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.3M	2M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	7.8M	3.5M	0.0	0.0	0.0	14.1M	48.2M	0.0	0.0
Other Current Liabilities	-221K	4.1M	395K	551K	1.7M	1.6M	3.4M	876K	479K
Total Current Liabilities	11.9M	15M	19.5M	8.7M	11.4M	26.6M	52.8M	3.8M	2.2M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	163.9M	14.2M	15M	0.0	84.9M	46.7M
Deferred Revenue (Non-Current)	7.8M	5.9M	0.0	0.0	0.0	0.0	2.9M	0.0	0.0
Other Non-Current Liabilities	1.5M	1.5M	1.1M	0.0	87K	0.0	180K	349K	510K
Total Non-Current Liabilities	50.1M	50.9M	32.3M	164.1M	43.1M	45.6M	3.1M	85.3M	47.2M
Capital Lease Obligations	40.8M	44.8M	33.2M	209K	28.9M	30.6M	0.0	0.0	0.0
Total Liabilities	62.1M	65.8M	51.8M	172.8M	54.5M	72.2M	55.9M	89.1M	49.4M
SHAREHOLDERS' EQUITY
Common Stock	9K	9K	8K	0.0	35K	34K	31K	14K	13K
Additional Paid-In Capital	435.1M	426.7M	352.9M	2.8M	310.9M	287.8M	236.2M	0.0	0.0
Retained Earnings	-383.8M	-266.6M	-183M	-101.8M	-180.1M	-95.4M	-68.9M	-49.1M	-29.9M
Accumulated Other Comprehensive Income/Loss	212K	268K	0.0	-5K	-62K	27K	54K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	792K	265K
Total Stockholders' Equity	51.4M	160.4M	169.9M	-99M	130.8M	192.5M	167.4M	-48.3M	-29.6M
Total Equity	51.4M	160.4M	169.9M	-99M	130.8M	192.5M	167.4M	-44.5M	-29.6M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M	0.0
SUMMARY
Total Liabilities & Equity	113.5M	226.2M	221.7M	73.7M	185.4M	264.7M	223.2M	44.5M	19.8M
Total Investments	53.3M	107.4M	0.0	23.5M	64.5M	1.8M	17.2M	0.0	0.0
Total Debt	43.5M	44.8M	33.2M	167M	45.6M	46M	0.0	84.9M	46.7M
Net Debt	21.7M	-10.9M	-132.9M	130.1M	-34M	-174.3M	-200.2M	42.7M	28.8M
Shares Outstanding	9,390,903	9,390,903	9,390,903	9,390,903	9,390,903	9,390,903	9,390,903	9,390,903	9,390,903

SEC Filings

KRRO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 19, 2026	May 19, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	June 10, 2026	2026	View Filing
S-3 S-3 N/A	March 13, 2026	March 13, 2026		View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 27, 2026	January 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 15, 2026	January 15, 2026	2026	View Filing

Showing 1 to 10 of 137 filings

Related Guides

Blog Categories

Continue your KRRO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.